retatrutide mechanism glp-1 gip glucagon triple agonist Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Retatrutide—A Game Changer in Obesity

Direct head-to-head trials and long-term data continue to accumulate

Reviews and primary research increasingly examine why dual and triple approaches outperform GLP-1 alone, exploring the synergistic effects of GIP co-agonism and glucagon receptor activation on both weight loss and metabolic parameters [1, 2, 3, 4]

Matza LS, Stewart KD, Land LF, Patel H, Boye KS (2022) Exit interviews examining the patient experience in clinical trials of tirzepatide for treatment of type 2 diabetes

doi: 10.1111/jdi.12450 [DOI] [PMC free article] [PubMed] [Google Scholar] 59.Weaver RE, Donnelly D, Wabitsch M, Grant PJ, Balmforth AJ

Sesame also offers a weight loss program that provides both branded weight loss and diabetes drugs and compounded semaglutide injections

Victoza (liraglutide) [package insert]